procedure or treatment of the associated and often highly recurring comorbidities resulting from disease progression. • The procedural impact of the therapy’s delivery method played a less significant role in its clinical attractiveness than the client had anticipated, which helped explain the original launch’s adoption issue, i.e., physicians had no compelling reason to change. • Only one treatment option on the market shared the therapy delivery method, a generic version that carried a major economic advantage. • The unique delivery method could reach areas of the body in-use technologies could not, and could treat – and prevent – the comorbidities related to disease progression. Based on these findings and others, Navigant made the following recommendations for the company

Join for free to read